Elucidating Substrate and Inhibitor Binding Sites on the Surface of GSK-3β and the Refinement of a Competitive Inhibitor

被引:27
作者
Licht-Murava, Avital [1 ]
Plotkin, Batya [1 ]
Eisenstein, Miriam [2 ]
Eldar-Finkelman, Hagit [1 ]
机构
[1] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel
[2] Weizmann Inst Sci, Dept Chem Res Support, IL-76100 Rehovot, Israel
关键词
protein kinase; molecular modeling; structure/function; inhibitors; drug design; parasite GSK-3; GLYCOGEN-SYNTHASE KINASE-3; INSULIN-RECEPTOR SUBSTRATE-1; PROTEIN-KINASE; PEPTIDE INHIBITORS; DRUG TARGET; PHOSPHORYLATION; GSK3; GLYCOGEN-SYNTHASE-KINASE-3; SPECIFICITY; MECHANISM;
D O I
10.1016/j.jmb.2011.02.036
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A molecular understanding of substrate recognition of protein kinases provides an important basis for the development of substrate competitive inhibitors. Here, we explored substrate recognition and competitive inhibition of glycogen synthase kinase (GSK)-3 beta using molecular and computational tools. In previous work, we described Gln89 and Asn95 within GSK-3 beta as important substrates binding sites. Here, we show that the cavity bordered by loop 89-QDKRFICN-95, located in the vicinity of the GSK-3 beta catalytic core, is a promiscuous substrate binding subsite. Mutations within this segment highlighted Phe93 as an additional essential contact residue for substrates' recognition. However, unlike Gln89 and Asn95, Phe93 was also important for the binding of our previously described substrate competitive inhibitor, L803 [KEAPPAPPQS(p)P], and its cell-permeable variant L803-mts. The effects of the substitution of charged or polar residues within L803 further suggested that binding to GSK-3 beta is governed by hydrophobic interactions. Our computational model of GSK-3 beta bound to L803 was in agreement with the experimental data. It revealed L803 binding with a hydrophobic surface patch and identified interactions between Pro8 (L803) and Phe93 (GSK-3 beta). Computational modeling of new L803 variants predicted that inhibition would be strengthened by adding contacts with Phe93 or by increasing the hydrophobic content of the peptide. Indeed, the newly designed L803 variants showed improved inhibition. Our study identified different and overlapping elements in GSK-3 beta substrate and inhibitor recognition and provides a novel example for model-based rational design of substrate competitive inhibitors for GSK-3. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:366 / 378
页数:13
相关论文
共 50 条
  • [41] Design, synthesis, and biological evaluation of tetrahydropyrimidine analogue as GSK-3β/Aβ aggregation inhibitor and anti-Alzheimer's agent
    Sukanya, Sukanya
    Bellver-Sanchis, Aina
    Choudhary, Bhanwar Singh
    Kumar, Sunil
    Perez, Belen
    Rodriguez, Anton Leandro Martinez
    Brea, Jose
    Grinan-Ferre, Christian
    Malik, Ruchi
    BIOORGANIC CHEMISTRY, 2024, 153
  • [42] Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor
    Kulkarni, Nalini H.
    Wei, Tao
    Kumar, Amar
    Dow, Ernst R.
    Stewart, Trent R.
    Shou, Jianyong
    N'cho, Mathias
    Sterchi, Diane L.
    Gitter, Bruce D.
    Higgs, Richard E.
    Halladay, David L.
    Engler, Thomas A.
    Martin, T. John
    Bryant, Henry U.
    Ma, Yanfei L.
    Onyia, Jude E.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2007, 102 (06) : 1504 - 1518
  • [43] Role of GSK-3β inhibitor TWS119 in protecting neurons against oxygen-glucose deprivation injury
    Yu, Xiaowen
    Wang, Xiaoqing
    Zeng, Shuxiong
    Tuo, Xiping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (10): : 14519 - 14525
  • [44] Rapid modulation of TRH and TRH-like peptide release in rat brain, pancreas, and testis by a GSK-3β inhibitor
    Pekary, Albert Eugene
    Stevens, Schetema A.
    Blood, James D.
    Sattin, Albert
    PEPTIDES, 2010, 31 (06) : 1083 - 1093
  • [45] Heck reaction and Stille coupling as the key steps in the synthesis of carbon-14-labeled gsk-3 inhibitor alsterpaullone
    Roth, Hans F.
    Li, Min
    Jiang, John
    Dulan, Dorothy K.
    Brendan, Mark B.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2011, 54 (05) : 272 - 277
  • [46] AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
    Santo, L.
    Vallet, S.
    Hideshima, T.
    Cirstea, D.
    Ikeda, H.
    Pozzi, S.
    Patel, K.
    Okawa, Y.
    Gorgun, G.
    Perrone, G.
    Calabrese, E.
    Yule, M.
    Squires, M.
    Ladetto, M.
    Boccadoro, M.
    Richardson, P. G.
    Munshi, N. C.
    Anderson, K. C.
    Raje, N.
    ONCOGENE, 2010, 29 (16) : 2325 - 2336
  • [47] Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest
    Damiens, E
    Baratte, B
    Marie, D
    Eisenbrand, G
    Meijer, L
    ONCOGENE, 2001, 20 (29) : 3786 - 3797
  • [48] Synergistic Killing Effect and Molecular Mechanism of Dual Targeting of Lymphoma By GSK-3 Inhibitor (9-ING-41) and BCL2 Inhibitor (ABT-199)
    Lei, Haohao
    Zhang, Yunxia
    Guo, Xutao
    BLOOD, 2024, 144 : 5844 - 5844
  • [49] The Mitochondrial Complex I Inhibitor Rotenone Induces Endoplasmic Reticulum Stress and Activation of GSK-3β in Cultured Rat Retinal Cells
    Han, Guoge
    Casson, Robert J.
    Chidlow, Glyn
    Wood, John P. M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (09) : 5616 - 5628
  • [50] SB-216763, a GSK-3 inhibitor, protects against aldosterone-induced cardiac, and renal injury by activating autophagy
    Zhang, Yi-De
    Ding, Xiao-Jun
    Dai, Hou-Yong
    Peng, Wei-Sheng
    Guo, Nai-Feng
    Zhang, Yuan
    Zhou, Qiao-Ling
    Chen, Xiao-Lan
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (07) : 5934 - 5943